/PRNewswire/ EyeYon Medical, a leading start-up company that develops innovative ophthalmic medical devices, announces Dr. Bakalash as Chief Medical Officer.
NES ZIONA, Israel, Feb. 22, 2022 /PRNewswire/ EyeYon Medical, a leading start-up company that develops innovative ophthalmic medical devices, announces Dr. Bakalash as Chief Medical Officer
/PRNewswire/ EyeYon Medical, a leading start-up company that develops innovative ophthalmic medical devices, announces Dr. Bakalash as Chief Medical Officer.
EyeYon Medical Receives CE Mark for its EndoArt® Implant to Treat Chronic Corneal Edema Font : A-A+
EndoArt® previously received Innovative Device Status by the Chinese NMPA, and Breakthrough Device Designation from the US Food and Drug Administration TEL AVIV, Israel, June 8, 2021 /PRNewswire/ EyeYon Medical, an Israeli start-up company developing a variety of ophthalmic products for vision-threatening conditions, announced today that it has received CE Mark for its EndoArt®, after clinical trials demonstrated safety and efficacy for treating chronic corneal edema. The CE Mark serves as approval by the European Union (EU) to commercialize EndoArt®, the world s first and only synthetic implant, which replaces the human endothelium that the human body can never regenerate. The current standard of care involves corneal transplantation of human tissue. This unique implant enables doctors to treat endothelial-related chronic corneal edema with a minimally invasive surger
EyeYon Medical Raises $25 million in Series C to Transform Corneal Care
USA - English
News provided by
Share this article
Share this article
TEL AVIV, Israel, March 15, 2021 /PRNewswire/ EyeYon Medical announced today the completion of a $25 million in a Series C funding, led by a global strategic leader in the ophthalmic industry and CR-CP Life Science Fund. Other participants in the round include Global Health Sciences (GHS) Fund (Quark Venture LP and GF Securities), BPC and existing investors Triventures, Rimonci, Pontifax and Diamond BioFund.
EyeYon Medical was founded in 2011 by Dr. Ofer Daphna, CEO Nahum Ferera MD, and Dr. Arie Marcovich, MD., and develops advanced technology to treat acute problems in the ophthalmic world. The latest round brings the total amount of capital raised by the company to $36 million.